Literature DB >> 1324793

Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumor xenografts to mitomycin Cł.

A M Malkinson1, D Siegel, G L Forrest, A F Gazdar, H K Oie, D C Chan, P A Bunn, M Mabry, D J Dykes, S D Harrison.   

Abstract

The enzyme DT-diaphorase (DTD; NAD(P)H:quinone oxidoreductase, EC 1.6.99.2), is an obligate two electron reductase which catalyzes reduction of a broad range of substrates, including quinones. We report here variations in DTD concentrations among different classes of lung tumors known also to vary in their responsiveness to cytotoxic agents. Small cell lung carcinomas (SCLCs) and cell lines derived from them have the low DTD activities and mRNA content characteristic of normal human lung, whereas non-small cell lung carcinomas (NSCLCs) have greatly elevated levels. DTD activity was increased up to 80-fold in NSCLC tumors relative to normal lung and 20-35-fold in NSCLC relative to SCLC cell lines. Increased DTD activity appeared to be a function of the NSCLC phenotype rather than a result of derivation from a cell type rich in DTD, since all histological classes of NSCLC showed this phenotype. In addition, where transfection of SCLC cell lines with the v-Ha-ras protooncogene caused a transition to a NSCLC phenotype, DTD activity was also elevated. Neuroendocrine-positive cells (SCLC, carcinoids, and a few NSCLC lines) typically had far lower DTD activities than did cell lines which lacked neuroendocrine markers (most NSCLC cells and mesotheliomas). High DTD activity may be exploited in the design of drugs which undergo bioreductive activation by this enzyme. Consistent with this, xenografts derived from NSCLC cell lines with high DTD that were grown in athymic nude mice were more susceptible to the antitumor quinone, mitomycin C, than were xenografts derived from SCLC cells containing low DTD. These data provide a mechanistic basis for the rational design of more effective bioreductive antitumor agents for use against NSCLC.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1324793

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

Review 1.  Enzymology of bioreductive drug activation.

Authors:  D Ross; H D Beall; D Siegel; R D Traver; D L Gustafson
Journal:  Br J Cancer Suppl       Date:  1996-07

2.  Reactive Oxygen Species Synergize To Potently and Selectively Induce Cancer Cell Death.

Authors:  Hyang Yeon Lee; Elizabeth I Parkinson; Carlotta Granchi; Ilaria Paterni; Dipak Panigrahy; Pankaj Seth; Filippo Minutolo; Paul J Hergenrother
Journal:  ACS Chem Biol       Date:  2017-04-07       Impact factor: 5.100

3.  Pharmacokinetics and derivation of an anticancer dosing regimen for the novel anti-cancer agent isobutyl-deoxynyboquinone (IB-DNQ), a NQO1 bioactivatable molecule, in the domestic felid species.

Authors:  Alycen P Lundberg; Joshua M Francis; Malgorzata Pajak; Elizabeth I Parkinson; Kathryn L Wycislo; Thomas J Rosol; Megan E Brown; Cheryl A London; Levent Dirikolu; Paul J Hergenrother; Timothy M Fan
Journal:  Invest New Drugs       Date:  2016-12-14       Impact factor: 3.850

4.  Cytotoxic mechanisms of anti-tumour quinones in parental and resistant lymphoblasts.

Authors:  A Halinska; T Belej; P J O'Brien
Journal:  Br J Cancer Suppl       Date:  1996-07

5.  Pharmacological approach towards the development of indolequinone bioreductive drugs based on the clinically inactive agent EO9.

Authors:  P M Loadman; M C Bibby; R M Phillips
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

6.  Quinone-induced activation of Keap1/Nrf2 signaling by aspirin prodrugs masquerading as nitric oxide.

Authors:  Tareisha Dunlap; Sujeewa C Piyankarage; Gihani T Wijewickrama; Samer Abdul-Hay; Michael Vanni; Vladislav Litosh; Jia Luo; Gregory R J Thatcher
Journal:  Chem Res Toxicol       Date:  2012-10-18       Impact factor: 3.739

7.  Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumours.

Authors:  D Hussein; S V Holt; K E Brookes; T Klymenko; J K Adamski; A Hogg; E J Estlin; T Ward; C Dive; G W J Makin
Journal:  Br J Cancer       Date:  2009-06-02       Impact factor: 7.640

8.  Evidence from ESI-MS for NQO1-catalyzed reduction of estrogen ortho-quinones.

Authors:  Nilesh W Gaikwad; Eleanor G Rogan; Ercole L Cavalieri
Journal:  Free Radic Biol Med       Date:  2007-08-03       Impact factor: 7.376

9.  Isolation and characterization of a mitomycin C-resistant variant of human colon carcinoma HT-29 cells.

Authors:  J H Lee; M Naito; M Nakajima; T Tsuruo
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

10.  P53 hot-spot mutants are resistant to ubiquitin-independent degradation by increased binding to NAD(P)H:quinone oxidoreductase 1.

Authors:  Gad Asher; Joseph Lotem; Peter Tsvetkov; Veronica Reiss; Leo Sachs; Yosef Shaul
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-21       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.